Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR) (WATCH-TMVR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mohamad Adnan (Mohamad) Alkhouli, MD
- Phone Number: 507-255-2504
- Email: alkhouli.mohamad@mayo.edu
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4W7
- Ottawa Heart Institute
-
-
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and Women ≥ 18 years of age;
- The patient has severe symptomatic mitral regurgitation meet criteria for the commercially available MitraClip;
- The patient also has documented paroxysmal, persistent, or permanent atrial fibrillation AND The patient meets the WATCHMAN labeling guidelines;
- The patient is eligible for short-term oral anticoagulation therapy with Warfarin or a direct oral anticoagulant;
- The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial;
- The patient is able and willing to return for required follow-up visits.
Exclusion Criteria:
- Mitral valve anatomy not deemed suitable for TMVr;
- Moderate to severe mitral stenosis (mean gradient >10 mmHg or MVA <1.5 cm2);
- Contraindication for short-term anticoagulation;
- The patient has intra-cardiac thrombus as visualized by TEE within 1 week prior to Watchman procedure;
- Prior occlusion of LAA;
- Implanted mechanical mitral valve;
The patient requires long-term warfarin therapy due to:
- Secondary to conditions such as prior arterial embolism or other indications such as pulmonary embolism or deep vein thrombosis within the previous 6 months.
- The patient is in a hypercoagulable state.
- Exclude the patient if per medical record documentation the patient meets any of the following criteria: • Thrombosis occurring at under 40 years age • Idiopathic or recurrent VTE (venous thromboembolism • Thrombosis at an unusual site (cerebral veins, hepatic veins, renal veins, IVC, mesenteric veins) • Family history of VTE or of inherited prothrombotic disorder, recurrence/extension of thrombosis while adequately anti-coagulated;
- The patient is actively enrolled in another trial of a cardiovascular device or an investigational drug (post-market study and registries are acceptable);
- The patient is pregnant, or pregnancy is planned during the course of the investigation if patient is of child bearing potential;
- Any clinically significant medical condition or presence of any laboratory abnormality performed prior to randomization that is considered by the investigator to be clinically important and could interfere with the conduct of the study or not meeting procedure guidelines for WATCHMAN or TMVr with MitraClip;
- The patient has a life expectancy of less than one year.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Treatment Group
This is not a randomized study.
Patients who are clinically indicated for both procedures will be offered the option to enroll in this registry for a combined procedure.
Otherwise, they will undergo TMVr and LAAO in two separate session as clinically indicated (standard of care).
|
The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy.
Device versions/types: MitraClip NTr, MitraClip XTr.
The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face.
Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause mortality rate
Time Frame: 45 days post procedure
|
Total number of Subject's Death
|
45 days post procedure
|
|
All-cause mortality rate
Time Frame: 1 Year post procedure
|
Total number of Subject's Death
|
1 Year post procedure
|
|
Serious Adverse Events (SAEs)
Time Frame: 45 days post procedure
|
Total number of Subject's experiencing SAEs such Stroke, life-threatening or major bleeding.
|
45 days post procedure
|
|
Serious Adverse Events (SAEs)
Time Frame: 1 Year post procedure
|
Total number of Subject's experiencing SAEs such Stroke, life-threatening or major bleeding.
|
1 Year post procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SAEs related to the Study devices
Time Frame: 1 Year
|
Total number of the Subject's to experience SAEs as related to Watchman and the LAAO devices.
|
1 Year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mohamad Adnan (Mohamad) Alkhouli, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 19-010047
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonvalvular Atrial Fibrillation
-
NCT07458191RecruitingNonvalvular Atrial Fibrillation
-
NCT05731882RecruitingNonvalvular Atrial Fibrillation
-
NCT04942873Not yet recruitingNonvalvular Atrial Fibrillation
-
NCT04586972Completed
-
NCT02674594CompletedNonvalvular Atrial Fibrillation
-
NCT02919982CompletedNonvalvular Atrial Fibrillation
-
NCT02007655CompletedNonValvular Atrial Fibrillation
-
NCT00171769CompletedPersistent Nonvalvular Atrial Fibrillation
-
NCT03374540CompletedNonvalvular Atrial Fibrillation
Clinical Trials on MitraClip TMVR and Watchman LAAO
-
NCT05144958RecruitingStroke | Atrial Fibrillation
-
NCT03706833Active, not recruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve Disease
-
NCT06213285Enrolling by invitationAtrial Fibrillation | Stroke, Ischemic | Device Related Thrombosis
-
NCT06675448RecruitingHeart Failure | Mitral Regurgitation | Valvular Heart Disease
-
NCT00129545CompletedStroke | Atrial Fibrillation
-
NCT04569734CompletedLeft Atrial Appendage Closure With WATCHMAN Device Utilizing an Intra-procedural ICE Probe
-
NCT04679714Not yet recruitingFunctional Mitral Regurgitation
-
NCT04679662Not yet recruitingDegenerative Mitral Valve Disease
-
NCT04676880Active, not recruitingAtrial Fibrillation | Anticoagulants and Bleeding Disorders
-
NCT03286088CompletedMitral Valve Regurgitation of Any Grade